Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Aug 3, 2022
Deals

Pair of Roche deals add allogeneic cell therapies, first-in-class fibrosis molecule

Deals provide substantial cash runway extensions for Poseida, Kiniksa
BioCentury | May 4, 2018
Financial News

Ex-Synageva team planning Kiniksa IPO

BioCentury | Apr 28, 2018
Financial News

Ex-Synageva team planning Kiniksa IPO

BioCentury | May 4, 2017
Translation in Brief

A window to IBD

Oncostatin M: a new biomarker and target in IBD
BioCentury | Jan 21, 2010
Targets & Mechanisms

Oncostatin's LIFR sentence

Items per page:
1 - 5 of 5